KR102632490B1 - 혈액 제제 및 프로파일링 - Google Patents

혈액 제제 및 프로파일링 Download PDF

Info

Publication number
KR102632490B1
KR102632490B1 KR1020187012951A KR20187012951A KR102632490B1 KR 102632490 B1 KR102632490 B1 KR 102632490B1 KR 1020187012951 A KR1020187012951 A KR 1020187012951A KR 20187012951 A KR20187012951 A KR 20187012951A KR 102632490 B1 KR102632490 B1 KR 102632490B1
Authority
KR
South Korea
Prior art keywords
proteins
blood
cell
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187012951A
Other languages
English (en)
Korean (ko)
Other versions
KR20180083853A (ko
Inventor
엘리자베스 카르스텐
벤 허버트
앨런 리들
카메론 힐
Original Assignee
생귀 바이오 피티와이. 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904075A external-priority patent/AU2015904075A0/en
Application filed by 생귀 바이오 피티와이. 엘티디 filed Critical 생귀 바이오 피티와이. 엘티디
Publication of KR20180083853A publication Critical patent/KR20180083853A/ko
Application granted granted Critical
Publication of KR102632490B1 publication Critical patent/KR102632490B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020187012951A 2015-10-07 2016-10-06 혈액 제제 및 프로파일링 Active KR102632490B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904075A AU2015904075A0 (en) 2015-10-07 Blood preparation and profiling
AU2015904075 2015-10-07
PCT/AU2016/000341 WO2017059477A1 (en) 2015-10-07 2016-10-06 Blood preparation and profiling

Publications (2)

Publication Number Publication Date
KR20180083853A KR20180083853A (ko) 2018-07-23
KR102632490B1 true KR102632490B1 (ko) 2024-02-02

Family

ID=58487130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012951A Active KR102632490B1 (ko) 2015-10-07 2016-10-06 혈액 제제 및 프로파일링

Country Status (10)

Country Link
US (2) US11243218B2 (cg-RX-API-DMAC7.html)
EP (2) EP3359962B1 (cg-RX-API-DMAC7.html)
JP (3) JP6824994B2 (cg-RX-API-DMAC7.html)
KR (1) KR102632490B1 (cg-RX-API-DMAC7.html)
CN (2) CN114019171A (cg-RX-API-DMAC7.html)
AU (1) AU2016334875B2 (cg-RX-API-DMAC7.html)
CA (1) CA3001154C (cg-RX-API-DMAC7.html)
HK (1) HK1258470A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201802754XA (cg-RX-API-DMAC7.html)
WO (1) WO2017059477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016374643B2 (en) * 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
JP2020502545A (ja) 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ. エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
US20240352423A1 (en) * 2021-03-10 2024-10-24 Terasaki Institute For Biomedical Innovation Methods and systems of producing products such as animal derived products
CN114081899A (zh) * 2021-11-02 2022-02-25 四川大学华西医院 一种富白细胞富血小板血浆的制备方法
JP7772425B2 (ja) 2022-03-23 2025-11-18 株式会社ミルテル ニコチンアミドアデニンジヌクレオチド(nad+)又はニコチンアミドモノヌクレオチド(nmn)を定量する方法、並びにその方法を実施するためのキット及び濾紙
WO2024010763A1 (en) * 2022-07-07 2024-01-11 Russell Biotech, Inc. Preparation of platelet free mononuclear cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156806A2 (en) * 2012-04-20 2013-10-24 Advancell Diagnosztika Kft Quantitative biomarkers in the erythrocyte membrane

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
PT706799E (pt) * 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
US5763280A (en) * 1997-01-21 1998-06-09 Coulter International Corp. Cyanide-free lytic reagent composition and method for hemoglobin and cell analysis
FR2778851B1 (fr) 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
US8431117B2 (en) 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
EP1355656A2 (en) 2000-07-24 2003-10-29 Gendel Limited Red blood cell as vehicle for agent-membrane translocation sequence conjugate
ES2498369T3 (es) 2002-04-16 2014-09-24 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Un marcador para medir cirrosis hepática
US7501286B2 (en) 2002-08-14 2009-03-10 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US7276382B2 (en) * 2003-10-02 2007-10-02 Noboru Horiguchi Blood testing method
GB0325483D0 (en) * 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US7803523B2 (en) * 2004-08-27 2010-09-28 University Health Network Whole blood preparation for cytometric analysis of cell signaling pathways
US20060166223A1 (en) * 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
WO2006123253A2 (en) 2005-03-29 2006-11-23 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US8530182B2 (en) 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith
CN102037355A (zh) 2008-03-04 2011-04-27 里奇诊断学股份有限公司 基于多重生物标记物板块诊断和监测抑郁症
US20110086424A1 (en) 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
WO2010147621A1 (en) 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods for ameliorating adverse effects associated with transfusion of aged red blood cells
SG177407A1 (en) * 2009-06-30 2012-02-28 Kaneka Corp Blood component separation system and separation material
CA2769889A1 (en) * 2009-08-13 2011-02-17 Basf Se Means and methods for diagnosing thyroid disorders
WO2011091154A2 (en) 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
AU2011212477A1 (en) 2010-02-08 2012-08-30 Piramal Imaging Sa F18-tyrosine derivatives for imaging bone metastases
WO2011127056A2 (en) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose
US20150111238A1 (en) 2011-05-31 2015-04-23 Singapore Health Services Pte. Ltd. Method for detecting disease biomarkers
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
CN105228596B (zh) 2013-05-10 2018-08-24 爱瑞德勒股份有限公司 用于制备载有一种或多种制药学感兴趣物质的红细胞的方法和由此得到的红细胞
JP6383920B2 (ja) * 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
KR20160073382A (ko) * 2013-10-04 2016-06-24 셀 아이디어스 피티와이 엘티디 세포 치료를 위한 바이오마커들
KR101845588B1 (ko) 2014-04-07 2018-04-05 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장
PT3297641T (pt) 2015-05-18 2025-10-09 Hemanext Inc Métodos de armazenamento de sangue total e respetivas composições
AU2016374643B2 (en) 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
JP2020502545A (ja) 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ. エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156806A2 (en) * 2012-04-20 2013-10-24 Advancell Diagnosztika Kft Quantitative biomarkers in the erythrocyte membrane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dzieciatkowska, Monika et al., Vox sanguinis, 2013, Vol. 105, pp 210-218. 1부.*
Pasini, Erica M. et al., Blood, 2006, Vol. 108, pp 791-801. 1부.*

Also Published As

Publication number Publication date
US20180306817A1 (en) 2018-10-25
EP3359962B1 (en) 2021-11-17
AU2016334875A8 (en) 2018-05-10
JP2021073453A (ja) 2021-05-13
WO2017059477A1 (en) 2017-04-13
SG11201802754XA (en) 2018-05-30
AU2016334875A1 (en) 2018-04-26
CN108700565A (zh) 2018-10-23
KR20180083853A (ko) 2018-07-23
EP3359962A1 (en) 2018-08-15
US11243218B2 (en) 2022-02-08
CN114019171A (zh) 2022-02-08
JP2023078210A (ja) 2023-06-06
HK1258470A1 (zh) 2019-11-15
EP4009047A1 (en) 2022-06-08
CA3001154C (en) 2023-10-17
CN108700565B (zh) 2021-10-29
AU2016334875B2 (en) 2022-10-27
US20240060997A1 (en) 2024-02-22
EP3359962A4 (en) 2019-03-06
CA3001154A1 (en) 2017-04-13
JP2018530766A (ja) 2018-10-18
JP6824994B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
US20240060997A1 (en) Blood Preparation and Profiling
JP7425903B2 (ja) プロテアーゼインヒビターを用いる血液プロファイリング
Reyes et al. A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS
Braun et al. The preanalytic phase in veterinary clinical pathology
Davis et al. Comparison of neutrophil CD64 expression, manual myeloid immaturity counts, and automated hematology analyzer flags as indicators of infection or sepsis
Sato et al. Flow cytometric analysis of Xenopus laevis and X. tropicalis blood cells using acridine orange
Kalyoncu Platelet indices in overweight and obese children
JP2012008044A (ja) 血小板活性化能の測定方法および抗血小板薬の評価方法
Pellicciotta et al. Development of a novel multiplexed assay for quantification of transforming growth factor-β (TGF-β)
Zhang et al. Dysregulated serum cytokine production in pediatric patients with β-thalassemia major
Törnudd et al. Quantification of platelet function-a comparative study of venous and arterial blood using a novel flow cytometry protocol
CN106290877A (zh) 急性髓系白血病粒细胞抗原表达量检测试剂盒及检测方法
Atere et al. Prognostic roles of c-reactive protein and erythrocyte sedimentation rate as acute phase reactants in mentally challenged subjects
Zuwała-Jagiełło et al. Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report
JP6206953B2 (ja) 成人t細胞白血病の発症し易さを試験する方法
Yucel et al. Effect of blood collection tube types on the measurement of human epidermal growth factor
Al-Faris et al. Altered expression levels of CD59, but not CD55, on red blood cells in stored blood
JP2005221323A (ja) 骨髄異形成症候群の検出方法
CN120831473A (zh) 用于电化学免疫分析的检测试剂、装置及检测方法
Pedersen et al. American Society for Veterinary Clinical Pathology (ASVCP) 49th Annual Meeting
LeSauteur et al. European Society for Veterinary Clinical Pathology (ESVCP) 13th Annual Congress

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230203

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231030

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240129

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration